De Sousa, Paul A. http://orcid.org/0000-0003-0745-2504
Perfect, Leo
Ye, Jinpei http://orcid.org/0000-0002-1441-6950
Samuels, Kay
Piotrowska, Ewa http://orcid.org/0000-0002-8899-2010
Gordon, Martin
Mate, Ryan
Abranches, Elsa http://orcid.org/0000-0003-4493-6065
Wishart, Thomas M. http://orcid.org/0000-0002-1973-6654
Dockrell, David H.
Courtney, Aidan
Funding for this research was provided by:
Innovate UK (85447)
Article History
Received: 16 October 2023
Accepted: 5 April 2024
First Online: 3 May 2024
Declarations
:
: The hESC line used in this study (RC9) was derived in the project entitled <i>Human Embryo Stem Cell Derivation for Clinical applications</i>. The project was approved by Scotland A Research Ethics Committee (Reference 07/MRE00/56, 31 July 2006). Research was conducted under licence from the UK Human Fertilisation and Embryology Authority (No. R0136). The processing and storage of hESC for human application was conducted under licence number 22631 from the UK Human Tissue Authority (De Sousa et al., 2016 a,b). Fresh full-term cord blood fractions were obtained from patients at Edinburgh Royal Infirmary, Obstetrics and Gynaecology department. The project was entitled <i>Examination of the potential of human tissue (adult) stem and progenitor cells for regenerative therapies (IRAS Project ID: 12361)</i>. This was approved by The South East Scotland Research Ethics Committee 2 (Reference 09/S1102/35, 30 September 2010).
: Not applicable.
: PDS and AC are co-founders and persons with controlling interests in Stroma Therapeutics Ltd. EA is currently an employee of AstraZenica. All other authors declare that they have no competing interests.